½ÃÀ庸°í¼­
»óǰÄÚµå
1327432

¿Ü»ó ÈÄ ½ºÆ®·¹½º Àå¾Ö(PTSD) Ãâ½Ã ¹× ÆÄÀÌÇÁ¶óÀÎ ¾àÁ¦ Æò°¡, ÀÓ»ó½ÃÇè, °æÀï ±¸µµ

Post-Traumatic Stress Disorder (PTSD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: GlobalData | ÆäÀÌÁö Á¤º¸: ¿µ¹® 76 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¿Ü»ó ÈÄ ½ºÆ®·¹½º Àå¾Ö(PTSD) Ä¡·áÁ¦ÀÇ ÇöÀç ¹× ÇâÈÄ °æÀï ±¸µµ¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ °¡´É¼ºÀÌ ÀÖ´Â ÁÖ¿ä µ¿Çâ, °æÀï ±¸µµ, °­·ÂÇÑ Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ °¡Áø ½Å±Ô Âü¿© ±â¾÷ÀÇ ¿ìÀ§¼º µî¿¡ ´ëÇØ µ¥ÀÌÅÍ¿¡ ±â¹ÝÇÑ °³¿ä¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä Á¶»ç °á°ú

Á¦3Àå Áúº´ »óȲ

  • Áúº´ÀÇ °³¿ä
  • ¿ªÇÐÀÇ °³¿ä
  • Ä¡·áÀÇ °³¿ä

Á¦4Àå ½ÃÆÇ¾à Æò°¡

  • ÁÖ¿ä ½ÃÆÇ¾à
  • ÀÛ¿ë±â¼­º° °³¿ä
  • Åõ¿© °æ·Îº° °³¿ä
  • ½ÃÆÇ¾à °³¿ä¿Í ÆÇ¸Å ¿¹Ãø

Á¦5Àå °¡°Ý°áÁ¤°ú »óȯ Æò°¡

  • ¿¬°£ Ä¡·áºñ
  • °¡°Ý°áÁ¤°ú »óȯ ½Ã°£

Á¦6Àå ÆÄÀÌÇÁ¶óÀÎ ÀǾàǰ Æò°¡

  • Á¦III»ó ÆÄÀÌÇÁ¶óÀÎ ÀǾàǰ
  • °³¹ß ´Ü°èº° °³¿ä
  • ºÐÀÚ À¯Çüº° °³¿ä
  • ÀÛ¿ë±â¼­º° °³¿ä
  • Åõ¿© °æ·Îº° °³¿ä
  • ÀǾàǰ ƯÀÌÀû »óÀüÀÌ ¼º°ø·ü(PTSR)°ú ½ÂÀÎÀÇ °¡´É¼º(LoA)
  • Ä¡·á ¿µ¿ª ¹× ÀûÀÀÁõ °íÀ¯ PTSR ¹× LoA

Á¦7Àå ÀÓ»ó½ÃÇè Æò°¡

  • ¿ª»çÀû °³¿ä
  • ´Ü°èº° °³¿ä
  • ÇöȲº° °³¿ä
  • ÁøÇàÁß ¹× °èȹÁßÀÎ ½ÃÇè ´Ü°èº° °³¿ä
  • °¡»ó ÄÄÆ÷³ÍÆ®¸¦ »ç¿ëÇÑ ÀÓ»ó½ÃÇè
  • Áö¿ªÀû °³¿ä
  • Áö¿ªº° ´ÜÀϱ¹ ¹× ´Ù±¹Àû ½ÃÇè
  • ½ºÆù¼­ »óÀ§ 20»ç¿Í ´Ü°èº° ³»¿ª
  • ½ºÆù¼­ »óÀ§ 20»çÀÇ ÇöȲº° ³»¿ª
  • ¿£µåÆ÷ÀÎÆ® ÇöȲº° °³¿ä
  • ÀÎÁ¾ ¹× ¹ÎÁ·º° °³¿ä
  • µî·Ï µ¥ÀÌÅÍ
  • ÀÓ»ó½ÃÇè »çÀÌÆ® »óÀ§ 20°³±¹
  • ¼¼°èÀÇ TOP 20 »çÀÌÆ®
  • ½ÇÇö °¡´É¼º ºÐ¼® - Áö¿ªÀû °³¿ä
  • ½ÇÇö °¡´É¼º ºÐ¼® - º¥Ä¡¸¶Å© ¸ðµ¨

Á¦8Àå °Å·¡ »óȲ

  • Áö¿ªº° ÇÕº´, Àμö, Àü·«Àû Á¦ÈÞ
  • ÃÖ±Ù ÇÕº´, Àμö, Àü·«Àû Á¦ÈÞ

Á¦9Àå »ó¾÷Àû Æò°¡

  • ÁÖ¿ä ½ÃÀå Âü¿© ±â¾÷

Á¦10Àå ÇâÈÄ ½ÃÀå ÃËÁø¿äÀÎ

Á¦11Àå ºÎ·Ï

KSA 23.08.17

Abstract

This reports provides a data-driven overview of the current and future competitive landscape in PTSD therapeutics.

Scope

GlobalData's PTSD: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the PTSD market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PTSD market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

  • 1.1 Contents
  • 1.2 Report Scope
  • 1.3 List of Tables and Figures
  • 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

  • 3.1 Disease Overview
  • 3.2 Epidemiology Overview
  • 3.3 Treatment Overview

4 Marketed Drugs Assessment

  • 4.1 Leading Marketed Drugs
  • 4.2 Overview by Mechanism of Action
  • 4.3 Overview by Route of Administration
  • 4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

  • 5.1 Annual Therapy Cost
  • 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

  • 6.1 Phase III Pipeline Drugs
  • 6.2 Overview by Development Stage
  • 6.3 Overview by Molecule Type
  • 6.4 Overview by Mechanism of Action
  • 6.5 Overview by Route of Administration
  • 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
  • 6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

  • 7.1 Historical Overview
  • 7.2 Overview by Phase
  • 7.3 Overview by Status
  • 7.4 Overview by Phase for Ongoing and Planned Trials
  • 7.5 Trials with Virtual Components
  • 7.6 Geographic Overview
  • 7.7 Single-Country and Multinational Trials by Region
  • 7.8 Top 20 Sponsors with Breakdown by Phase
  • 7.9 Top 20 Sponsors with Breakdown by Status
  • 7.10 Overview by Endpoint Status
  • 7.11 Overview by Race and Ethnicity
  • 7.12 Enrollment Data
  • 7.13 Top 20 countries for Trial Sites
  • 7.14 Top 20 Sites Globally
  • 7.15 Feasibility Analysis - Geographic Overview
  • 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

  • 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
  • 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

  • 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

  • 11.1 Methodology
  • 11.2 Methodology - Sales Forecast
  • 11.3 Methodology - Pricing and Reimbursement
  • 11.4 Methodology - PTSR and LoA Analysis
  • 11.5 About the Authors
  • 11.6 Contact Us
  • 11.7 Disclaimer
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦